Expression of CD30 in patients with acute graft-versus-host disease.
Acute GVHD (aGVHD) remains a major source of morbidity after allogeneic hematopoietic cell transplantation. CD30 is a cell-surface protein expressed on certain activated T cells. We analyzed CD30 expression on peripheral blood T-cell subsets and soluble CD30 levels in 26 patients at the time of presentation of aGVHD, before the initiation of treatment, compared with 27 patients after hematopoietic cell transplantation without aGVHD (NONE). Analysis by flow cytometry showed that patients with aGVHD had a greater percentage of CD30 expressing CD8(+) T cells with the difference especially pronounced in the central memory subset (CD8(+)CD45RO(+)CD62L(+)): GVHD median 12.4% (range, 0.8%-33.4%) versus NONE 2.1% (0.7%, 17.5%), P < .001. There were similar levels of CD30 expression in naive T cells, CD4(+) T cells, and regulatory (CD4(+)CD127(low)CD25(+)) T cells. Plasma levels of soluble CD30 were significantly greater in patients with GVHD: median 61.7 ng/mL (range, 9.8-357.1 ng/mL) versus 17.4 (range, 3.7-142.4 ng/mL) in NONE (P < .001). Immunohistochemical analysis of affected intestinal tissue showed many CD30(+) infiltrating lymphocytes present. These results suggest that CD30 expression on CD8(+) T-cell subsets or plasma levels of soluble CD30 may be a potential biomarker for aGVHD. CD30 may also represent a target for novel therapeutic approaches for aGVHD.
Department of Hematology/Oncology, Bone Marrow Transplantation Unit, Massachusetts General Hospital, Boston, MA 02114, USA. ychen6@partners.org
Yi-Bin
YB
Chen
Sean
S
McDonough
Robert
R
Hasserjian
Heidi
H
Chen
Erin
E
Coughlin
Christina
C
Illiano
In Sun
IS
Park
Madan
M
Jagasia
Thomas R
TR
Spitzer
Corey S
CS
Cutler
Robert J
RJ
Soiffer
Jerome
J
Ritz
D000208:Acute Disease; D000954:Antigens, Surface / Q000378:metabolism; D015415:Biomarkers / Q000378:metabolism; D001706:Biopsy; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism*; D005434:Flow Cytometry / Q000379:methods*; D006086:Graft vs Host Disease / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy; D019337:Hematologic Neoplasms / Q000628:therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007156:Immunologic Memory / Q000276:immunology; D007422:Intestines / Q000276:immunology / Q000473:pathology; D017730:Ki-1 Antigen / Q000097:blood / Q000276:immunology / Q000378:metabolism*; D012995:Solubility; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism*; D014184:Transplantation, Homologous
D000954:Antigens, Surface; D015415:Biomarkers; D017730:Ki-1 Antigen